Details

Autor(en) / Beteiligte

• Bockisch, Andreas
• Kroschinsky, Frank
• Heuser, Michael
• Hochhaus, Andreas
• Höffkes, Heinz-Gert
• Behringer, Dirk
• Tometten, Mareike
• Grieshammer, Martin
• Grigoleit, Götz U.
• Schmalz, Oliver
• Jordan, Karin
• Bernhard, Helga
• Gaska, Tobias
• Giagounidis, Aristoteles
• Schroers, Roland
• Martens, Uwe M.
• Klapper, Wolfram
• Jöckel, Karl-Heinz
• Nonnemacher, Michael
• Hüttmann, Andreas
• Wilop, S.
• Tometten, M.
• Keller, U.
• de Wit, M.
• Weissinger, F.
• Behringer, D.
• Nückel, H.
• Schroers, R.
• Trenn, G.
• Hertenstein, B.
• Bernhard, H.
• Wörns, M.-A.
• Kroschinsky, F.
• Selbach, J.
• Petrasch, S.
• Balleisen, J. S.
• Schütte, J.
• Dienst, A.
• Germing, U.
• Dührsen, U.
• von Verschuer, U.
• Höffkes, H.-G.
• Runde, V.
• Spohn, C.
• Dürk, H.
• Kofahl-Krause, D.
• Heuser, M.
• Müller-Tidow, C.
• Martens, U. M.
• Strumberg, D.
• La Rosée, P.
• Hochhaus, A.
• Link, H.
• Held, G.
• Baldus, C.
• Naumann, R.
• Schulte, K.
• Limmroth, C.
• Schwarzer, A.
• Niederwieser, D.
• Platzbecker, U.
• Heil, G.
• Schwalenberg, M.
• Stephany, M.
• Mesters, R.
• Karsten, I. E.
• Mahlmann, S.
• Steiniger, H.
• Maschmeyer, G.
• Jordan, K.
• Grube, M.
• Herr, W.
• Raghavachar, A.
• Fett, W.
• Sandmann, M.
• Krohn, T.
• Brenner, W.
• Plotkin, M.
• Franzius, C.
• Kotzerke, J.
• Hautzel, H.
• Bengel, F. M.
• Haberkorn, U.
• Freesmeyer, M.
• Lützen, U.
• Kluge, R.
• Larisch, R.
• Holzinger, J.
• Schäfer, W.
• Weckesser, M.
• Nyuyki, F.
• Römer, W.
• Brink, I.
• Marienhagen, J.
• Pöpperl, G.
• Jöckel, K.-H.
• Nonnemacher, M.
• Rekowski, J.
• Scherag, A.
• Neuhäuser, M.

Titel

Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial

Ist Teil von

• Blood Neoplasia, 2024-09, Vol.1 (3), p.100018, Article 100018

Ort / Verlag

Elsevier Inc

Erscheinungsjahr

2024

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• •Interim PET predicted outcome in aggressive non-Hodgkin lymphoma, but iPET-based treatment changes failed to improve outcome.•Treatment of relapse often differed from protocol-based recommendations, with best results after allogeneic transplantation. [Display omitted] The PETAL (Positron Emission Tomography–Guided Therapy of Aggressive Non-Hodgkin Lymphomas) trial investigated whether treatment intensification after 2 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP; plus rituximab [R] for CD20+ lymphomas) improved survival in aggressive non-Hodgkin lymphoma. A total of 754 patients (87.5%) had a negative and 108 (12.5%) had a positive interim positron emission tomography (iPET) scan. iPET-positive patients were randomly assigned to receive another 6 (R-)CHOP cycles or 6 blocks of a more intensive protocol. Interim PET-negative patients received another 4 cycles of R-CHOP with or without 2 additional doses of R. After a median follow-up of 4 years, treatment intensification had not improved outcome. These results were confirmed after 10.3 years of follow-up. The present analysis also describes the management of relapse that was part of the study. Among 240 relapsing patients, 94 of 133 autologous transplantation–eligible patients (70.7%) and 16 of 107 ineligible patients (15.0%) received the salvage treatments recommended in the study protocol. Adherence to recommendations had no impact on outcome. Best results were seen after allogeneic transplantation, followed by autologous transplantation and treatment without transplantation (5-year overall survival rate, 64.3% vs 45.5% vs 22.6%), but patients undergoing allogeneic transplantation were significantly younger and their disease was well controlled at the time of transplantation. Early outcome prediction by iPET, alone or in combination with other methods, is a powerful tool to investigate the value of immunological treatment options for patients with a poor response to chemotherapy. This trial was registered at ClinicalTrials.gov as #NCT00554164.